The Future of IBM and Watson Health
Overview of IBM and Watson Health
IBM and Watson Health have long and prosperous relationships that have benefited both parties. IBM sold its Watson Health assets to a third party in April 2021. This sale was designed to expand Watson Health’s reach and create new business opportunities for the company.
However, there are still many questions about the future for Watson Health and its relationship with IBM. So let’s take a closer look at their current situation and what lies ahead:
History of IBM
Established in 1911, International Business Machines (IBM) has become an iconic technology company. Its empire stretches from developing software and hardware to providing IT and consulting services. For almost three decades, IBM created every type of modern computing technology during the 20th century.
In the 1980s, IBM developed the personal computer (PC). It also released its first PC-compatible software program – VisiCalc – a spreadsheet program that allowed people to easily perform complex calculations. To this day, software created by IBM considerably influences different areas of computer science and project management.
IBM has made strong investments in science and today it is a leader in Artificial Intelligence (AI) research with its AI brand, Watson. Built on top of sophisticated “cognitive” algorithms that power natural language processing, Watson can read human language, form relationships between words, and recognize key concepts in healthcare and finance information.
Watson Health was formed in 2015 when IBM acquired two healthcare-focused businesses: Explorys and Phytel. Explorys provided IBM with data storage capabilities for healthcare information while Phytel provided disease management solutions for medical professionals. Together these acquisitions paved the way for IBM to create Watson Health. This health analytics platform was designed to answer challenging healthcare questions using data collected from millions of patients across thousands of medical studies worldwide.
Overview of Watson Health
IBM Watson Health is one of IBM’s most recognized divisions and is focused on developing cutting-edge solutions that improve healthcare outcomes. This business unit leverages its Watson platform to deliver “cognitive computing” systems that allow clinicians, researchers, and data scientists to benefit from the vast amount of data generated from everyday activities. From healthcare providers to health plans to pharma organisations, IBM Watson Health has created technologies for various industries that would greatly benefit from the power of Big Data.
IBM Watson Health provides solutions in many areas. These solutions are created in various ways but all involve the use of the Watson platform, including artificial intelligence (AI) elements such as machine learning and natural language processing. For example, solutions can be used for healthcare providers and payers to better manage financial workflow and resources. Additionally, intelligence can be used in predictive analytics or drug discovery; and analysis can also be used in diagnostic imaging or population health management.
IBM has invested heavily into this technology-driven space and continues to collaborate with industry participants in areas such as:
- diabetes care
- value-based care
- genomics research
- predictive analytics
From its integrated services portfolio which ties together consumer families electronic health records with genomic imager services or data analytics related to public health; organisations turn to IBM Watson Health for robust platforms that help make sense of it all.
IBM sells Watson Health assets
IBM announced earlier this year that it had sold its Watson Health assets to a consortium of five tech companies, signalling a shift in its long-term strategy. This move has been a topic of discussion among analysts and industry watchers trying to understand the motivations behind the sale.
In this article, we will explore some of the reasons why IBM decided to sell its Watson Health assets:
Strategic Shift in Focus
As part of its recent restructuring efforts, IBM has sold some of its assets related to Watson Health. Instead, the multinational technology company has decided to focus on products and services related to emerging technologies such as artificial intelligence (AI), cloud computing, blockchain, and quantum computing.
IBM’s CEO, Arvind Krishna, said that selling the Watson Health assets was part of the company’s strategic shift towards new and innovative technologies. He believes this move would help the firm stay ahead of the competition regarding technological innovations in vital areas such as healthcare, cybersecurity and financial services.
Apart from Watson Health, IBM has also sold some of its other non-core assets including Seterus (mortgage servicing), Unica (marketing automation) and Tailored Brands (clothing). These divestitures are expected to reduce costs by about $2 billion for the company over two years and focus its resources more on AI solutions for enterprise customers. By doing so, IBM aims to boost its customer offerings significantly while managing costs better.
One of the primary financial considerations for IBM in selling its Watson Health assets was the need to free up resources that could be used to focus on other projects. This included taking money out of a divested product line and putting it instead into research, development, and other areas that would lead to more future innovation. This might include new products, services or technologies.
It was believed that Watson Health was not a strategic fit for IBM’s long-term corporate goals. This made the company’s health care endeavours less appealing when better returns on investment might be obtained from other business areas.
IBM is focused on developing cloud-based solutions and artificial intelligence (AI) capabilities. Continuing investment in those areas would reap greater rewards than investing in Watson Health which had become increasingly reliant on partnerships with third parties such as hospital groups, insurance companies and pharmaceutical firms. In addition, the sale allowed IBM to cut costs and put resources into other ventures where they would get quicker, higher returns on their investments.
Impact of The Sale on Watson Health
In 2021, IBM announced plans to sell its Watson Health assets to a joint venture between Truveta and ClearDATA. This sale has raised questions about the future of the Watson Health division and how it will impact the healthcare industry going forward.
In this article, we will discuss the implications of this sale and what it could mean for Watson Health:
Changes in The Scope of Services
In 2018, IBM announced the sale of the Watson Health imaging business to Merging Technologies SA. As part of the $1 billion sale, IBM will retain a minority stake in the company and continue collaborating with key partners and customers. Moving forward without its imaging business, IBM intends to focus more on services and cloud-delivered technologies for managing health data.
Under the new operational model established by this new agreement, Watson Health will enhance delivery of its existing artificial intelligence (AI) platform with an expanded role in managing data from multiple sources in a secure environment. As a result, the platform will be able to collect, store and analyse patient data from multiple sites faster than ever before. Furthermore, with cloud-based services connected directly to health systems and care providers, Watson Health will facilitate better patient monitoring and processes such as population health analytics and precision medicine initiatives.
The changes in scope of services related to Watson Health offer a great opportunity for healthcare providers worldwide looking to integrate AI and analytics into their organisations’ clinical pathways while improving patient outcomes. As a result of this strategic move, IBM is now better positioned to address challenges associated with remotely accessed data sources like wearables, digital diagnostics tools and real-time patient feedback within hospital settings. In addition, by leveraging the vast potential of big data generated through AI technology across healthcare networks worldwide, organisations can create safer environments for patients and healthier populations over time.
Impact on Existing Customers
The sale of Watson Health to Truven Health Analytics had a major impact on existing customers who did business with IBM. Many companies had to redefine their strategies and reevaluate their commitment to investing in Watson as part of their health IT solutions. Some companies felt that the sale removed much of the novelty from Watson’s services, while others were concerned about the sustainability of their relationship with Truven.
The sale also changed the employees and partners associated with IBM’s Watson Health division. IBM laid off nearly 2,700 employees as part of its restructuring plans, meaning those individuals had to find new positions outside the company. Additionally, many partners experienced disruption as a result of changes at IBM and some even chose to discontinue business arrangements with Truven after the sale closed.
Moreover, there were implications for innovation in healthcare as well—Truven promised to emphasise applied information systems in its approach to health data science but didn’t elaborate on how it planned to implement these practices compared to what was offered under IBM’s leadership. Therefore, it is unclear what kinds of advances will be made going forward and how that might affect:
- Existing customers
- New customers who may look for access to Truven’s resources in the future
Implications for The Future of IBM and Watson Health
The news that IBM is selling their Watson Health assets is a significant move for the company and the healthcare industry. The move could signify a change in IBM’s strategy and could also have broad implications for Watson Health itself. This article will explore the implications for the future of IBM and Watson Health.
What Will IBM Focus on Next?
As IBM and Watson Health continue to grow and develop, their focus on transforming healthcare will remain ever-present. They focus on helping healthcare organisations drive better results from their operations, improve patient care quality, and advance advancements in data science and artificial intelligence (AI). Additionally, they are continuing to explore potential applications for blockchain technologies to further spur advances in AI capabilities.
IBM is also making strides into developing new technologies that could make a real difference in clinical decision-making. One example is the Watson for Clinical Trial Matching service, designed to match study participants with trials that best match their demographic or clinical profile. As a result, it can help quickly identify clinical trial opportunities across various diseases and treatments based not just on age or gender criteria but also on patients’ DNA profiles, family histories and drug tolerance profiles.
In addition to these projects centred around improving the patient experience with care delivery, IBM is also exploring how their technology can shift the focus onto cost containment measures without sacrificing quality care outcomes. By building predictive models based on healthcare datasets from across different regions and using machine learning algorithms such as natural language processing (NLP), IBM hopes to uncover valuable insights about health costs which can be used by hospitals and insurers alike to reduce overall expenditure while ensuring positive patient outcomes remain intact.
Finally, IBM is expanding its scope beyond healthcare by crossing over into other industries like finance and retail and applying its knowledge in other areas such as automotive engineering and enterprise solutions software development. Combining these new fields of expertise and advances in artificial intelligence should pave the way for a truly transformative future within IBM’s portfolio.
What Will The Future of Watson Health Look Like?
The future of IBM and Watson Health looks very promising. IBM’s investment in Watson Health demonstrates the company’s commitment to making healthcare smarter and more accessible to everyone. With its expansive data network, predictive analytics, machine learning, and AI capabilities, Watson Health has the potential to revolutionise the healthcare industry.
Watson Health has already made great progress in patient-centred care through its partnerships with hospitals such as Dell Medical Center and University of Wisconsin School of Medicine. Using machine learning and big data analytics, Watson is helping clinicians improve patient outcomes and reduce errors in diagnosis by identifying patterns that can be used to predict the best treatments for an individual patient.
IBM is investing heavily in collaborations between Watson Health, life sciences, and pharmaceutical companies. For example, through collaborations with Novartis, Pfizer, Sanofi, Merck, UCBpharma and Bayer Healthcare-Watson Intelligence Consortium (WIBC), IBM is working to speed up drug development processes by leveraging its data networks for clinical insight about diseases as well as potential treatment pathways for new drugs in development.
In addition to its collaborations with life sciences companies, IBM is partnering with tech startups worldwide through their Global Entrepreneurs Program (GEP). Through GEP they are providing access to technical resources that can help budding entrepreneurs develop innovative solutions related to data science/machine learning such as genomics/precision medicine applications or advanced analytics tools that can be built on top of IBM’s suite of products including Watson and cloud computing offerings like Bluemix or MQTT protocols.
The future looks bright for Watson Health which could soon become a vital partner in efforts to use AI-based approaches across multiple industries worldwide including finance/banking security educational systems health care etc. As technology continues to advance so too will our capabilities allowing us to create better, more efficient ways of doing common tasks associated with our daily lives such as going shopping, paying bills or dealing with medical issues thus ensuring a brighter future for all humankind.
In conclusion, IBM’s decision to sell its Watson Health assets is a bold move that will help the company focus on areas such as artificial intelligence and cloud computing. The sale will also enable IBM to invest more in research and development, allowing it to become a leader in the healthcare industry.
IBM’s Watson Health business has provided invaluable insights into the healthcare industry and will continue to be a major player even after the sale of its assets.
Summary of The Sale and its Implications
IBM’s sale of the IBM Watson Health business to Truven Health Analytics in April of 2021 was an important move for the company. The sale is part of IBM’s ongoing strategy to develop new technologies and services, while exiting businesses that don’t directly align with its core business objectives. In addition, the sale effectively positions IBM to better align its resources and investments with market opportunities and customer needs.
The sale provides Truven Health Analytics with access to powerful AI technology that it can use to deliver innovative healthcare solutions. By combining its existing analytics expertise, with access to IBM Watson Health’s clinical and hardware-focused technology, Truven will be able to expand its offering into areas where it lacks current capabilities such as:
- population health insights
- life sciences research tools
- reduced cost precision oncology treatments
- improved lab results interpretation tools
For IBM the sale helps them refocus their resources towards future growth opportunities within their key business focus areas; cloud computing, enterprise IT solutions and big data analysis. It also reinforces their commitment to providing healthcare organisations globally with powerful analytics technology. So while Watson Health no longer resides as an independent subsidiary at IBM, both companies will benefit from this partnership in various ways for years to come.
Final Thoughts on The Future of IBM and Watson Health
In the years to come, IBM and Watson Health will no doubt continue to move forward with innovative medical technology and services. By leveraging AI and predictive analytics, Watson Health has emerged as an industry-leading platform. This platform enables providers to increase patient satisfaction while reducing healthcare costs.
Moving forward, IBM will enable healthcare organisations to improve efficiency by centralising data sharing via interoperability standards and providing better engagement strategies through consumer experience management capabilities. It is expected that with the growth of telehealth, AI-assisted diagnostics, home health care, personalised medicine and precision medicine; IBM will shape resource optimization in the health space for a more connected understanding into patient care.
The future of IBM and Watson Health looks promising as it continues to build on its current offerings for better health outcomes for people worldwide.
tags = ibm sells watson health, ibm sells healthcare data and analytics, watson health business, clinical clouds need, healthcare data platform, ibm ibm health 1bstreetjournal, sources watson health 1bstreetjournal, ibm ibm watson health 1bstreetjournal, sources ibm ibm watson health 1bstreetjournal, watson healthcare data, ibm watson healthcare data analytics, watson cloud-based access